

B2

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: <i>Pontiac Osteopathic Hospital Pontiac, MI</i> REPORT NUMBER(S) <i>2007-001</i>		2. NRC/REGIONAL OFFICE U.S. Nuclear Regulatory Commission Region III 2443 Warrenville Road Suite 210 Lisle, Illinois 60532-4351	
3. DOCKET NUMBER(S) <i>030-02041</i>	4. LICENSEE NUMBER(S) <i>21-04081-03</i>	5. DATE(S) OF INSPECTION <i>May 23, 2007</i>	

LICENSEE:
The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

1. Based on the inspection findings, no violations were identified.

2. Previous violation(s) closed.

3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Deborah A. Piskura	<i>Deborah A. Piskura</i>	<i>5/23/07</i>

Docket File Information

**SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION**

1. LICENSEE Pontiac Osteopathic Hospital REPORT 2007-001		2. NRC/REGIONAL OFFICE Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532	
3. DOCKET NUMBER(S) 030-02041	4. LICENSE NUMBER(S) 21-04081-01	5. DATE(S) OF INSPECTION May 23, 2007	
6. INSPECTION PROCEDURES USED 87130 and 87131	7. INSPECTION FOCUS AREAS 03.01, 03.02, 03.03, 03.04, 03.05, 03.06, 03.07, and 03.08		
SUPPLEMENTAL INSPECTION INFORMATION			
1. PROGRAM CODE(S) 02120	2. PRIORITY G 3	3. LICENSEE CONTACT Eduard Kotlyarov, M.D., RSO	4. TELEPHONE NUMBER 248-338-5632
<input checked="" type="checkbox"/> Main Office Inspection		Next Inspection Date: <u>May 2010</u>	
<input type="checkbox"/> Field		<hr/>	
<input type="checkbox"/> Temporary Job Site		<hr/>	

PROGRAM SCOPE

This licensee was a community hospital with authorization to use materials in Sections 35.100, 35.200, and 35.300. The nuclear medicine department was staffed with 2 full-time technologists who performed approximately 150-180 diagnostic nuclear medicine procedures per month. The department received unit doses and bulk Tc-99m from a licensed nuclear pharmacy. The department performed a full spectrum of diagnostic studies. Typically, in a year, the hospital administered 3-5 NaI-131 dosages for hyperthyroidism. Radioiodine was obtained from a licensed nuclear pharmacy in capsule form. The hospital retained the services of a consultant physicist to audit the nuclear medicine radiation safety program on a quarterly basis.

This inspection consisted of interviews with licensee personnel, a review of selected records, tour of the nuclear medicine department, and independent measurements. The inspection included observations of security of byproduct material, use of personnel monitoring, dose calibrator QA checks, and area surveys.